Investment analysts at Argus initiated coverage on shares of Charles River Laboratories International (NYSE:CRL) in a research note issued on Wednesday, The Fly reports. The firm set a “buy” rating on the medical research company’s stock.

A number of other equities analysts have also issued reports on the company. SunTrust Banks reaffirmed a “buy” rating and issued a $113.00 target price on shares of Charles River Laboratories International in a research report on Friday, November 17th. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Robert W. Baird set a $117.00 target price on Charles River Laboratories International and gave the company a “buy” rating in a research report on Monday, November 13th. ValuEngine lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Bank of America cut their target price on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $106.63.

Charles River Laboratories International (CRL) opened at $104.57 on Wednesday. Charles River Laboratories International has a 52-week low of $73.81 and a 52-week high of $119.05. The stock has a market capitalization of $4,920.86, a P/E ratio of 20.41, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. During the same period in the prior year, the company posted $1.18 EPS. Charles River Laboratories International’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts anticipate that Charles River Laboratories International will post 5.13 earnings per share for the current year.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Over the last three months, insiders have purchased 10,500 shares of company stock worth $2,885 and have sold 1,056,776 shares worth $2,011,952. Corporate insiders own 2.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Quantbot Technologies LP grew its stake in shares of Charles River Laboratories International by 291.7% in the third quarter. Quantbot Technologies LP now owns 1,414 shares of the medical research company’s stock worth $117,000 after purchasing an additional 1,053 shares in the last quarter. YorkBridge Wealth Partners LLC grew its stake in shares of Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after purchasing an additional 891 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after purchasing an additional 526 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Charles River Laboratories International by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of Charles River Laboratories International by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after purchasing an additional 43 shares in the last quarter. 96.27% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/13/argus-begins-coverage-on-charles-river-laboratories-international-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

The Fly

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.